S&P 500   3,923.59 (-1.88%)
DOW   33,454.90 (-1.45%)
QQQ   281.03 (-2.30%)
AAPL   142.64 (-2.72%)
MSFT   244.75 (-2.18%)
META   114.24 (-6.69%)
GOOGL   96.86 (-2.63%)
AMZN   88.24 (-3.04%)
TSLA   178.25 (-2.30%)
NVDA   159.93 (-3.71%)
NIO   13.14 (+2.66%)
BABA   91.48 (+1.06%)
AMD   70.18 (-4.67%)
T   19.05 (+1.60%)
MU   53.43 (-1.13%)
CGC   3.58 (-17.13%)
F   13.11 (-2.02%)
GE   84.76 (+0.12%)
DIS   92.57 (-3.50%)
AMC   6.81 (-8.59%)
PYPL   71.67 (-2.65%)
PFE   49.90 (-1.64%)
NFLX   304.35 (-2.64%)
S&P 500   3,923.59 (-1.88%)
DOW   33,454.90 (-1.45%)
QQQ   281.03 (-2.30%)
AAPL   142.64 (-2.72%)
MSFT   244.75 (-2.18%)
META   114.24 (-6.69%)
GOOGL   96.86 (-2.63%)
AMZN   88.24 (-3.04%)
TSLA   178.25 (-2.30%)
NVDA   159.93 (-3.71%)
NIO   13.14 (+2.66%)
BABA   91.48 (+1.06%)
AMD   70.18 (-4.67%)
T   19.05 (+1.60%)
MU   53.43 (-1.13%)
CGC   3.58 (-17.13%)
F   13.11 (-2.02%)
GE   84.76 (+0.12%)
DIS   92.57 (-3.50%)
AMC   6.81 (-8.59%)
PYPL   71.67 (-2.65%)
PFE   49.90 (-1.64%)
NFLX   304.35 (-2.64%)
S&P 500   3,923.59 (-1.88%)
DOW   33,454.90 (-1.45%)
QQQ   281.03 (-2.30%)
AAPL   142.64 (-2.72%)
MSFT   244.75 (-2.18%)
META   114.24 (-6.69%)
GOOGL   96.86 (-2.63%)
AMZN   88.24 (-3.04%)
TSLA   178.25 (-2.30%)
NVDA   159.93 (-3.71%)
NIO   13.14 (+2.66%)
BABA   91.48 (+1.06%)
AMD   70.18 (-4.67%)
T   19.05 (+1.60%)
MU   53.43 (-1.13%)
CGC   3.58 (-17.13%)
F   13.11 (-2.02%)
GE   84.76 (+0.12%)
DIS   92.57 (-3.50%)
AMC   6.81 (-8.59%)
PYPL   71.67 (-2.65%)
PFE   49.90 (-1.64%)
NFLX   304.35 (-2.64%)
S&P 500   3,923.59 (-1.88%)
DOW   33,454.90 (-1.45%)
QQQ   281.03 (-2.30%)
AAPL   142.64 (-2.72%)
MSFT   244.75 (-2.18%)
META   114.24 (-6.69%)
GOOGL   96.86 (-2.63%)
AMZN   88.24 (-3.04%)
TSLA   178.25 (-2.30%)
NVDA   159.93 (-3.71%)
NIO   13.14 (+2.66%)
BABA   91.48 (+1.06%)
AMD   70.18 (-4.67%)
T   19.05 (+1.60%)
MU   53.43 (-1.13%)
CGC   3.58 (-17.13%)
F   13.11 (-2.02%)
GE   84.76 (+0.12%)
DIS   92.57 (-3.50%)
AMC   6.81 (-8.59%)
PYPL   71.67 (-2.65%)
PFE   49.90 (-1.64%)
NFLX   304.35 (-2.64%)

Eli Lilly and - LLY Stock Forecast, Price & News

$367.60
-1.69 (-0.46%)
(As of 12/6/2022 02:28 PM ET)
Add
Compare
Today's Range
$365.63
$370.64
50-Day Range
$311.10
$374.76
52-Week Range
$231.87
$375.25
Volume
44,749 shs
Average Volume
2.89 million shs
Market Capitalization
$349.29 billion
P/E Ratio
55.20
Dividend Yield
1.05%
Price Target
$366.80

Eli Lilly and MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.81 Rating Score
Upside/​Downside
0.4% Upside
$367.55 Price Target
Short Interest
Healthy
0.66% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.25
Upright™ Environmental Score
News Sentiment
0.18mentions of Eli Lilly and in the last 14 days
Based on 43 Articles This Week
Insider Trading
Acquiring Shares
$374.91 M Bought Last Quarter
Proj. Earnings Growth
18.04%
From $7.76 to $9.16 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.15 out of 5 stars

Medical Sector

6th out of 1,023 stocks

Pharmaceutical Preparations Industry

2nd out of 501 stocks

LLY stock logo

About Eli Lilly and (NYSE:LLY) Stock

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and and its competitors with MarketBeat's FREE daily newsletter.

LLY Stock News Headlines

Four Healthcare Stocks To Watch This Week (LLY)
Healthcare has long been a wise investment, as the industry consistently grows yearly. Some analysts believe that trend will continue.
Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market? (LLY)
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry.
These 10 Stocks Have Resilient Profit Margins
Goldman Lists Stocks with Resilient Profit Margins
What 12 Analyst Ratings Have To Say About Eli Lilly
Covid Cases Are Rising. L.A. Could Bring Back Masks.
Why You Can’t Find Wegovy, the Weight-Loss Drug
FDA Pulls Lilly’s Covid Antibody Drug
See More Headlines
Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and and its competitors with MarketBeat's FREE daily newsletter.

LLY Company Calendar

Last Earnings
10/25/2021
Ex-Dividend for 9/9 Dividend
8/12/2022
Dividend Payable
9/09/2022
Ex-Dividend for 12/9 Dividend
11/14/2022
Today
12/06/2022
Dividend Payable
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/02/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
53245710
Employees
35,000
Year Founded
1876

Price Target and Rating

Average Stock Price Forecast
$367.55
High Stock Price Forecast
$446.00
Low Stock Price Forecast
$286.00
Forecasted Upside/Downside
-0.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81
Research Coverage
16 Analysts

Profitability

Net Income
$5.58 billion
Pretax Margin
22.40%

Debt

Sales & Book Value

Annual Sales
$28.32 billion
Cash Flow
$9.21 per share
Book Value
$9.57 per share

Miscellaneous

Free Float
949,038,000
Market Cap
$349.29 billion
Optionable
Optionable
Beta
0.35

Social Links


Key Executives

  • Mr. David A. RicksMr. David A. Ricks (Age 54)
    Chairman, CEO & Pres
    Comp: $4.1M
  • Ms. Anat  AshkenaziMs. Anat Ashkenazi (Age 49)
    Sr. VP & CFO
    Comp: $1.91M
  • Dr. Daniel M. Skovronsky M.D.Dr. Daniel M. Skovronsky M.D. (Age 48)
    Ph.D., Sr. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Labs
    Comp: $2.16M
  • Mr. Diogo Rau
    Sr. VP & Chief Information and Digital Officer
  • Mr. Jacob S. Van NaardenMr. Jacob S. Van Naarden (Age 37)
    Sr. VP, CEO of Loxo Oncology & Pres of Lilly Oncology
    Comp: $2.01M
  • Mr. Donald A. ZakrowskiMr. Donald A. Zakrowski
    Chief Accounting Officer & VP of Fin.
  • Mr. Martin Bott MIBS (Age 59)
    VP of Fin. & Special Projects
  • Kevin Hern
    VP of Investor Relations
  • Ms. Anat Hakim J.D. (Age 53)
    Sr. VP, Gen. Counsel & Sec.
  • Mr. Alonzo  WeemsMr. Alonzo Weems
    Sr. VP and Chief Ethics & Compliance Officer













LLY Stock - Frequently Asked Questions

Should I buy or sell Eli Lilly and stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LLY shares.
View LLY analyst ratings
or view top-rated stocks.

What is Eli Lilly and's stock price forecast for 2023?

16 Wall Street analysts have issued twelve-month price objectives for Eli Lilly and's shares. Their LLY share price forecasts range from $286.00 to $436.00. On average, they anticipate the company's share price to reach $366.80 in the next twelve months. This suggests that the stock has a possible downside of 0.7%.
View analysts price targets for LLY
or view top-rated stocks among Wall Street analysts.

How have LLY shares performed in 2022?

Eli Lilly and's stock was trading at $276.22 at the beginning of 2022. Since then, LLY shares have increased by 33.7% and is now trading at $369.29.
View the best growth stocks for 2022 here
.

Are investors shorting Eli Lilly and?

Eli Lilly and saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 5,610,000 shares, a decrease of 8.0% from the October 31st total of 6,100,000 shares. Based on an average daily volume of 3,000,000 shares, the days-to-cover ratio is currently 1.9 days. Approximately 0.7% of the company's stock are sold short.
View Eli Lilly and's Short Interest
.

When is Eli Lilly and's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our LLY earnings forecast
.

How were Eli Lilly and's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) released its earnings results on Monday, October, 25th. The company reported $1.94 EPS for the quarter, missing the consensus estimate of $1.98 by $0.04. The firm had revenue of $6.77 billion for the quarter, compared to analysts' expectations of $6.64 billion. Eli Lilly and had a net margin of 20.63% and a trailing twelve-month return on equity of 80.80%. Eli Lilly and's revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.54 earnings per share.
Read the conference call transcript
.

How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?

Eli Lilly and announced a quarterly dividend on Monday, October 17th. Stockholders of record on Tuesday, November 15th will be given a dividend of $0.98 per share on Friday, December 9th. This represents a $3.92 annualized dividend and a dividend yield of 1.06%. The ex-dividend date is Monday, November 14th.
Read our dividend analysis for LLY
.

Is Eli Lilly and a good dividend stock?

Eli Lilly and (NYSE:LLY) pays an annual dividend of $3.92 per share and currently has a dividend yield of 1.05%. The company has been increasing its dividend for 8 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 58.86%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LLY will have a dividend payout ratio of 42.79% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LLY.

How will Eli Lilly and's stock buyback program work?

Eli Lilly and declared that its board has initiated a stock buyback program on Monday, May 3rd 2021, which permits the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase up to 2.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's leadership believes its shares are undervalued.

What guidance has Eli Lilly and issued on next quarter's earnings?

Eli Lilly and issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of $7.70-$7.85 for the period, compared to the consensus EPS estimate of $7.99. The company issued revenue guidance of $28.50 billion-$29.00 billion, compared to the consensus revenue estimate of $28.85 billion.

What is David A. Ricks' approval rating as Eli Lilly and's CEO?

399 employees have rated Eli Lilly and Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.

What other stocks do shareholders of Eli Lilly and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

What is Eli Lilly and's stock symbol?

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Who are Eli Lilly and's major shareholders?

Eli Lilly and's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Lilly Endowment Inc. (10.92%), Vanguard Group Inc. (7.64%), State Street Corp (3.53%), Primecap Management Co. CA (2.95%), Price T Rowe Associates Inc. MD (2.61%) and Jennison Associates LLC (1.06%). Insiders that own company stock include Aarti S Shah, Acquisition Corp Kearny, Alfonso G Zulueta, Alonzo Weems, Donald A Zakrowski, Ilya Yuffa, Jackson P Tai, Lilly Endowment Inc, Marschall S Runge, Melissa S Barnes, Myles O'neill and Stephen F Fry.
View institutional ownership trends
.

How do I buy shares of Eli Lilly and?

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eli Lilly and's stock price today?

One share of LLY stock can currently be purchased for approximately $369.29.

How much money does Eli Lilly and make?

Eli Lilly and (NYSE:LLY) has a market capitalization of $350.89 billion and generates $28.32 billion in revenue each year. The company earns $5.58 billion in net income (profit) each year or $6.66 on an earnings per share basis.

How many employees does Eli Lilly and have?

The company employs 35,000 workers across the globe.

Does Eli Lilly and have any subsidiaries?
The following companies are subsidiares of Eli Lilly and: 1096401 B.C. Unlimited Liability Company, ARMO BioSciences Inc, ARMO Bioscience, Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma, Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Dermira, Devices for Vascular Intervention(DVI), Disarm Therapeutics, Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services Inc, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly de Centro America S.A., Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc, Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, Kinsale Financial Services Unlimited Company, Lilly (Shanghai) Management Co. Ltd, Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly China Research and Development Co. Ltd., Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Lylly Centre for Clinical Pharmacology PTE. LTD., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Pharmaserve-Lilly S.A.C.I., Physio-Control, SGX Pharmaceuticals, SGX Pharmaceuticals Inc, Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.
Read More
How can I contact Eli Lilly and?

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The official website for the company is www.lilly.com. The company can be reached via phone at (317) 276-2000, via email at johnson_philip_l@lilly.com, or via fax at 317-276-4878.

This page (NYSE:LLY) was last updated on 12/6/2022 by MarketBeat.com Staff